Cost-Effectiveness Analysis of Antibiotic Therapy for Community-Acquired Pneumonia at Mimika Regional Hospital, Central Papua

https://doi.org/10.22146/jmpf.98701

Bustanul Arifin(1*), Fidel Yoel Junovray Sattu(2), Anshar Saud(3)

(1) *) Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, South Sulawesi *) Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, Groningen
(2) Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, South Sulawesi
(3) Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, South Sulawesi
(*) Corresponding Author

Abstract


Background: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide, affecting the lower respiratory tract. It is caused by diverse pathogens, including bacteria, viruses, fungi, and chemical exposures. Antibiotics, such as ceftriaxone, are widely used for treatment. However, the high economic burden associated with CAP management necessitates a cost-effectiveness analysis to optimize treatment strategies.

Objectives: This study aimed to evaluate the cost-effectiveness of three antibiotic regimens—co-amoxiclav, meropenem + levofloxacin, and ceftriaxone—for CAP inpatients at Mimika Hospital, Indonesia, to identify the most efficient therapeutic option.

Methods: A retrospective, cross-sectional observational study was conducted using medical records of CAP patients admitted to Mimika Hospital between January and December 2021. Inclusion criteria were patients aged ≥18 years who received a single antibiotic regimen. Treatment effectiveness was assessed based on hospitalization duration (≤3 days) and physician-reported recovery. Cost-effectiveness was evaluated using the Average Cost-Effectiveness Ratio (ACER).

Results: A total of 120 pneumonia inpatients were analyzed, predominantly male (60%) and aged 26–45 years (34%). The most frequently administered antibiotic was ceftriaxone (51%), followed by co-amoxiclav (29%) and meropenem + levofloxacin (20%). Co-amoxiclav demonstrated the highest clinical effectiveness (88.57%) and the lowest median total cost (IDR 2,696,114), resulting in the lowest ACER value (IDR 2,696,114/effectiveness unit) and a dominant ICER status. In contrast, meropenem + levofloxacin showed moderate effectiveness (75%) at the highest cost (IDR 3,088,961), with an ICER of IDR 18,538.64. Ceftriaxone had the lowest effectiveness (65.57%) and the highest ACER (IDR 44.443,22), indicating poor cost-efficiency. These findings position co-amoxiclav as the most cost-effective regimen across both clinical and economic parameters.

Conclusion: Co-amoxiclav is the most cost-effective antibiotic regimen for CAP inpatients at Mimika Hospital, offering optimal therapeutic outcomes at a lower cost. These findings support its recommendation as the first-line treatment for CAP in similar healthcare settings


Keywords


ceftriaxone; co-amoxiclav; cost-effectiveness; levofloxacin; meropenem; pneumonia

Full Text:

PDF


References

  1. Vardhmaan J, Vashisht R, Yilmaz G, Bhardwaj A. Pneumonia Pathology. Pneumonia Pathol 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526116/. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526116/. Accessed: 20 Mar. 2025.
  2. Shoar S, Musher D. Etiology of Community-acquired Pneumonia in Adults: A Systematic Review. Open Forum Infect Dis 2020;7(Supplement_1):1–10. doi:10.1093/ofid/ofaa439.1679.
  3. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, … Whitney CG. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2019;200(7):E45–E67. doi:10.1164/rccm.201908-1581ST.
  4. Wongsurakiat P, Chitwarakorn N. Severe community-acquired pneumonia in general medical wards: Outcomes and impact of initial antibiotic selection. BMC Pulm Med 2019;19(1):1–10. doi:10.1186/s12890-019-0944-1.
  5. Sharma R, Sandrock CE, Meehan J, Theriault N. Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin. Clin Drug Investig 2020;40(10):947–960. doi:10.1007/s40261-020-00953-z.
  6. Kementrian_Kesehatan_RI. Riset Kesehatan Dasar Indonesia 2013 (Indonesian Basic Health Research). Jakarta: 2013. doi:10.1126/science.127.3309.1275.
  7. Kementerian_Kesehatan_Republik_Indonesia. Laporan Riskesdas 2018 Indonesia (Indonesian Basic Health Research). Jakarta: Kementrian Kesehatan Republik Indonesia; 2018.
  8. BPS_Provinsi_Papua. Provinsi Papua dalam Angka. Papua: 2022.
  9. Fatin MNA, Rahayu C, Suwantika AA. Analisis Efektivitas Biaya Penggunaan Antibiotik pada Pasien Community-acquired Pneumonia di RSUP Dr. Hasan Sadikin Bandung (Cost-Effectiveness Analysis of Antibiotic Use in Patients with Community-Acquired Pneumonia at Dr. Hasan Sadikin General Hospital,. Indones J Clin Pharm 2019;8(3):228–236. doi:10.15416/ijcp.2019.8.3.228.
  10. Kim DD, Basu A. How Does Cost-Effectiveness Analysis Inform Health Care Decisions? AMA J Ethics 2021;23(8):E639-47.
  11. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, … Whitney CG. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Supplement article (Suppl2)):S27-72. doi:10.1086/511159.
  12. Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, … Ramirez JA. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J 2010;36(1):128–134. doi:10.1183/09031936.00130909.
  13. Lee MS, Oh JY, Kang CI, Kim ES, Park S, … Kiem S. Guideline for antibiotic use in adults with community-acquired pneumonia. Infect Chemother 2018;50(2):160–198. doi:10.3947/ic.2018.50.2.160.
  14. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for Economics Evaluation of Healthcare Programmes. Fourth. Oxford University Press; 2015.
  15. Rascati KL. Essentials of Pharmacoeconomics. United Stated of America: Lippincott Williams & Wilkins, a Wolters Kluwer business.; 2009.
  16. Jang SY, Cha Y, Yoo J Il, Yu YT, Kim JT, … Choy W. Effect of pneumonia on all-cause mortality after elderly hip fracture: A korean nationwide cohort study. J Korean Med Sci 2020;35(2):1–8. doi:10.3346/jkms.2020.35.e9.
  17. Kuo TJ, Hsu CL, Liao PH, Huang SJ, Hung YM, Yin CH. Nomogram for pneumonia prediction among children and young people with cerebral palsy: A population-based cohort study. PLoS One 2020;15(7):1–14. doi:10.1371/journal.pone.0235069.
  18. Dang TT, Eurich DT, Weir DL, Marrie TJ, Majumdar SR. Rates and risk factors for recurrent pneumonia in patients hospitalized with community-acquired pneumonia: Population-based prospective cohort study with 5 years of follow-up. Clin Infect Dis 2014;59(1):74–80. doi:10.1093/cid/ciu247.
  19. GBD_2019_Diseases_and_Injuries_Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9.
  20. Badriah E, . I. Pneumonia in Toddlers: Association of Characteristics and Nutritional Status. J Appl Food Nutr 2022;2(2):52–59. doi:10.17509/jafn.v2i2.42720.
  21. Ratnasari F, Sutrisno S, Noorma N. Factors Associated with Pneumonia Incidence in Toddlers in the Pediatric Ward of RSUD Kudungga Kutai Timur. Asian J Soc Humanit 2023;1(10):744–752. doi:10.59888/ajosh.v1i10.100.
  22. Le Roux DM, Myer L, Nicol MP, Zar HJ. Incidence and severity of childhood pneumonia in the first year of life in a South African birth cohort: The Drakenstein Child Health Study. Lancet Glob Heal 2015;3(2):e95–e103. doi:10.1016/S2214-109X(14)70360-2.
  23. Ares-Blanco S, Álvarez MP, Larrondo IG, Muñoz C, Ruiz VA, … Guisado-Clavero M. SARS-CoV-2 pneumonia follow-up and long COVID in primary care: A retrospective observational study in Madrid city. PLoS One 2021;16(9 September):1–12. doi:10.1371/journal.pone.0257604.
  24. Søgaard M, Nielsen RB, Schønheyder HC, Nørgaard M, Thomsen RW. Nationwide trends in pneumonia hospitalization rates and mortality, Denmark 1997-2011. Respir Med 2014;108(8):1214–1222. doi:10.1016/j.rmed.2014.05.004.
  25. Laelasari N, Shoaliha M, Wada FH, Prima A, Poddar S. Cost Effectiveness Analysis Treatment of Pediatric Pneumonia Antibiotic Ceftriaxon and Cefotaxime at Dr. Chasbullah Abdulmadjid Hospital. Malaysian J Med Heal Sci 2023;19(Supplement 9):102–106. doi:10.47836/mjmhs.19.s9.15.
  26. Saha L, Kaur S, Khosla P, Kumari S, Rani A. Pharmacoeconomic Analysis of Drugs Used in the Treatment of Pneumonia in Paediatric Population in a Tertiary Care Hospital in India-A Cost-of-Illness Study. Med Sci (Basel, Switzerland) 2017;5(4):1–10. doi:10.3390/medsci5040033.
  27. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, … Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: A randomized open-label controlled trial. Crit Care 2012;16(3):1–13. doi:10.1186/cc11405.
  28. Park SY, Si HJ, Eom JS, Lee JS. Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem. J Int Med Res 2019;47(12):5977–5985. doi:10.1177/0300060519879336.
  29. Zhen X, Lundborg CS, Sun X, Hu X, Dong H. Economic burden of antibiotic resistance in ESKAPE organisms: A systematic review. Antimicrob Resist Infect Control 2019;8(137):1–23. doi:10.1186/s13756-019-0590-7.
  30. Purba AKR, Ascobat P, Muchtar A, Wulandari L, Dik JW, … Postma MJ. Cost-effectiveness of culture-based versus empirical antibiotic treatment for hospitalized adults with community-acquired pneumonia in Indonesia: A real-world patient-database study. Clin Outcomes Res 2019;11:729–739. doi:10.2147/CEOR.S224619.
  31. Smith KJ, Wateska A, Nowalk MP, Raymund M, Lee BY, … Fine MJ. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med 2013;28(9):1157–1164. doi:10.1007/s11606-013-2400-x.
  32. Acharya VK, Padyana M, Unnikrishnan B, Anand R, Acharya PR, Juneja DJ. Microbiological profile and drug sensitivity pattern among community acquired pneumonia patients in tertiary care centre in Mangalore, Coastal Karnataka, India. J Clin Diagnostic Res 2014;8(6):4–6. doi:10.7860/JCDR/2014/7426.4446.
  33. Bendixen HK, Kjeldsen LJ. Treatment of pneumonia: Adherence to a hospital policy. Eur J Hosp Pharm 2013;20(3):189–191. doi:10.1136/ejhpharm-2012-000049.
  34. Uda A, Tokimatsu I, Koike C, Osawa K, Shigemura K, … Yano I. Antibiotic de-escalation therapy in patients with community-acquired nonbacteremic pneumococcal pneumonia. Int J Clin Pharm 2019;41(6):1611–1617. doi:10.1007/s11096-019-00926-z.
  35. Ott SR, Hauptmeier BM, Ernen C, Lepper PM, Nüesch E, … Bauer TT. Treatment failure in pneumonia: Impact of antibiotic treatment and cost analysis. Eur Respir J 2012;39(3):611–618. doi:10.1183/09031936.00098411.



DOI: https://doi.org/10.22146/jmpf.98701

Article Metrics

Abstract views : 2380 | views : 1596

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats